Publicaciones en colaboración con investigadores/as de Charité (13)

2022

  1. After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181

  2. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366

2018

  1. Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment

    RMD Open, Vol. 4, Núm. 1

  2. Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current european rheumatology practice

    Patient Preference and Adherence, Vol. 12, pp. 2007-2014

2017

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 6, pp. 960-977

2016

  1. Evidence for treating rheumatoid arthritis to target: Results of a systematic literature search update

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 16-22

2011

  1. Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study

    BMC Musculoskeletal Disorders, Vol. 12

  2. Treating rheumatoid arthritis to target: Multinational recommendations assessment questionnaire

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 11, pp. 1999-2002

2010

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 964-975

  2. The Eular recommendations for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs

    Rheumatologia, Vol. 24, Núm. 4, pp. 143-158

2008

  1. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients withd-heumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 67, Núm. 10, pp. 1365-1373

  2. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

    Annals of the Rheumatic Diseases, Vol. 67, Núm. 10, pp. 1360-1364

  3. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

    Arthritis Care and Research, Vol. 59, Núm. 10, pp. 1371-1377